Transdermal Buprenorphine: A Viewpoint by Rudolf Likar

ISSN： 0012-6667

Source： Drugs, Vol.63, Iss.19, 2003-01, pp. : 2011-2012

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Transdermal Buprenorphine

By Evans H.C. Easthope S.E.

Drugs, Vol. 63, Iss. 19, 2003-01 ,pp. : 1999-2010

Adis International

Access to resources Recommend Favorite

Transdermal Oxybutynin: A Viewpoint by Michael Chancellor

By Chancellor M.

Drugs & Aging, Vol. 20, Iss. 11, 2003-01 ,pp. : 865-866

Adis International

Access to resources Recommend Favorite

Transdermal Testosterone: A Viewpoint by Adrian S. Dobs

By Dobs A.S.

Drugs, Vol. 55, Iss. 2, 1998-02 ,pp. : 259-259

Adis International

Access to resources Recommend Favorite

Buprenorphine overdose: Intoxication following transdermal administration in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1233, 2009-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis

By Wen Warren

Expert Opinion on Drug Safety, Vol. 12, Iss. 3, 2013-05 ,pp. : 309-319

Informa Healthcare

Access to resources Recommend Favorite